Literature DB >> 27606444

Combined insulin/GLP-1 pens near market.

Eva von Schaper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27606444     DOI： 10.1038/nbt0916-897a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  FDA launches priority vouchers for neglected-disease drugs.

Authors:  Emily Waltz
Journal:  Nat Biotechnol       Date:  2008-12       Impact factor: 54.908

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

4.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.

Authors:  Simon Thom; Neil Poulter; Jane Field; Anushka Patel; Dorairaj Prabhakaran; Alice Stanton; Diederick E Grobbee; Michiel L Bots; K Srinath Reddy; Raghu Cidambi; Severine Bompoint; Laurent Billot; Anthony Rodgers
Journal:  JAMA       Date:  2013-09-04       Impact factor: 56.272
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.